Luxturna gene therapy for sight loss on the NHS

/in /by

The Overcompensation With Too Many Collages: Important Lifelines Age influences immune function. pharmacy online viagra online Winds known to increase pulmonary arterial resistance are avoided.
This week, the BBC reported that gene therapy may become available on the NHS for those with visual impairments. With a commercial price of £613,410 per person, the NHS have managed to come to an agreement with global drug company Novartis over treatment with voretigene neparvovec (commercially known as Luxturna) and it is expected that treatment will be available from January 2020.

Let’s go through the main points:

  • Eligibility for the treatment is very specific - Voretigene neparvovec is targeted at those with inherited retinal dystrophies due to a mutation in the RPE65 gene, which aids the production of proteins vital to normal vision. The National Institute for Health and Care Excellence (NICE) estimate that approximately 86 people in England will be eligible.
  • Voretigene neparvovec aims to stabilise vision and prevent further sight loss - Unfortunately the treatment does not aim to restore vision that has already been lost.
  • Location may be important - NICE lists NHS England as the only NHS consultee for the proposed treatment. Furthermore, in reports, quotes from the NHS have come from Simon Stevens, the CEO of NHS England. This could suggest that the treatment will only be available to those living in England and Wales (who are legally obliged to fund NICE guidance). Those with the condition in Scotland and Northern Ireland will have to wait on separate decisions to be made. Additionally, according to a statement by NHS England, the treatment will initially be rolled out in three national specialist centres across the UK. Making it available to other hospitals later is an option and not mandatory.
  • Injections in the eye - The treatment is administered by a one-time injection under the retina of each eye. Normally, one eye will be treated first, with the other treated after at least 6 days. The injections aim to introduce a healthy version of the RPE65 gene which can then help production of the protein needed for normal vision.
  • Long-term effects are unclear - Studies have shown shorter term benefits (3 to 4 years) but longer term effects are uncertain. However, clinical experts feel that there is a “biological rationale” for the effects of the treatment to remain.
  • There are side effects - As with most treatments, there are potential side effects and these can be found on Luxturna’s website. Some of the more serious ones include eye infections, permanent decline in visual acuity or sharpness of central vision, as well as further sight loss due to various potential changes to the eye.
  • Not set in stone - This treatment is still currently in progress with final evaluation determination expected to conclude by 20th September 2019. It is still a possibility (admittedly a minute one) that the availability of Luxturna could be delayed. However, the NICE guidance is expected to be published on the 9th October 2019, which then gives NHS England three months to make it available “as an option”.

Please see the NICE website for full details and status of the treatment.